CLHLF yields 5.09% · PFE yields 6.13%● Live data
📍 CLHLF pulled ahead of the other in Year 1
Combined, CLHLF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CLHLF + PFE for your $10,000?
COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. It offers restoration products, including conventional composites, bulk-fill composites, CAD/CAM solutions, core build-ups, bondings, etching gels, temporary materials, luting, curing lights, and characterizations; and endodontics products, such as posts, rotary and hand files, irrigation solutions, obturation and sealing materials, Gutta-percha and paper points, endo engines, apex locators, and endo accessories. The company also provides prosthetics comprising bite registration, retractions, A-silicones, C-silicones, and accessories; and treatment auxiliaries consisting of dental rolls and dispensers, cotton pellets and dispensers, aspirator tips, dental dams and dam kits, dental dam clamps and accessories, dental scalers, electrosurgery, and occlusion verification products. In addition, it offers infection control products, which include ultrasonic cleaning units, patient bibs, headrest covers, and sterile covers; rotary instruments, such as diamond and carbide burs, polishers, kits, and accessories; and laboratory products comprising gingiva masks, lab putty products, model making products, waxes, occlusion control products, accessories, HP burs, and silicone polishers. The company was formerly known as Medisize Holding AG and changed its name to COLTENE Holding AG in April 2008. COLTENE Holding AG was incorporated in 2005 and is headquartered in Altstätten, Switzerland.
Full CLHLF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.